Department of Medical Education, Gundersen Health System, La Crosse, Wisconsin.
Department of Medical Research, Gundersen Health System, La Crosse, Wisconsin.
Surg Obes Relat Dis. 2024 Jul;20(7):644-651. doi: 10.1016/j.soard.2024.03.009. Epub 2024 Mar 13.
Many types of cancer have been found to be associated with being overweight or obese. Literature has demonstrated a reduction in cancer risk in patients who have undergone bariatric surgery.
To compare the incidence and types of new cancer diagnoses, cumulative cancer incidence, cancer risk, and overall survival in patients with obesity who underwent bariatric surgery with that of those who did not.
Community-based academic medical center.
We retrospectively compared the rates and types of new incident cancers in a bariatric surgery cohort (Bariatric group) with those of a non-surgical cohort (Comparison group). The Comparison group was chosen from patients who had a clinic visit in our health system within 30 days of each bariatric surgical operation and matched on age, sex, and body mass index. Patients who had a cancer diagnosis prior to having bariatric surgery were excluded from the Bariatric group and patients who had a cancer diagnosis prior to the clinic visit on which they were matched were excluded from the Comparison group. Relative risk of cancer by type was calculated. Chi-square and Fisher exact tests were used for categorical data analysis, and Wilcoxon rank-sum for continuous data. The Kaplan Meier estimator with the log-rank test was used to compare overall survival between groups, while competing risks survival analysis with the Gray test for equality was used to compare cancer incidence in the Surgery group with that in the Comparison group.
After matching, the Bariatric group had 1593 patients and the Comparison group had 2156. The Bariatric and Comparison groups had 82 and 222 new incident cancer cases, respectively (P < .001). The 10-year incidence of any new cancer in the Bariatric group was 6.5%, compared with an incidence of 12.1% in the Comparison group (P < .001). Relative risk of cancer in the Bariatric group was lower than that of the Comparison group, with the greatest differences in endometrial (88.8%), kidney (77.4%), thyroid (72.9%), and ductal carcinoma in situ (71.2%) cancers. The 10-year overall survival rate was higher in the Bariatric group than in the Comparison group, 93.3% versus 80.6%, respectively (P < .001).
Bariatric surgery reduces the risk for developing cancer and offers survival advantage when compared with similar patients who do not undergo bariatric surgery.
许多类型的癌症都与超重或肥胖有关。文献表明,接受减重手术的患者癌症风险降低。
比较肥胖患者接受减重手术后新发癌症的发生率和类型、累积癌症发生率、癌症风险和总体生存率,与未接受手术的患者进行比较。
基于社区的学术医疗中心。
我们回顾性比较了减重手术队列(减重组)与非手术队列(对照组)中新发癌症的发生率和类型。对照组是从我们医疗系统中在每次减重手术 30 天内就诊的患者中选择的,并按年龄、性别和体重指数匹配。排除在接受减重手术前已诊断出癌症的患者,同时排除在就诊前已诊断出癌症的患者。计算癌症类型的相对风险。采用卡方检验和 Fisher 精确检验进行分类数据分析,Wilcoxon 秩和检验进行连续数据分析。Kaplan-Meier 估计和对数秩检验用于比较组间总体生存率,竞争风险生存分析和 Gray 检验用于比较手术组和对照组的癌症发生率。
匹配后,减重组有 1593 例患者,对照组有 2156 例患者。减重组和对照组分别有 82 例和 222 例新发癌症病例(P<0.001)。减重组的 10 年任何新发癌症的发生率为 6.5%,而对照组为 12.1%(P<0.001)。减重组的癌症相对风险低于对照组,其中子宫内膜癌(88.8%)、肾癌(77.4%)、甲状腺癌(72.9%)和导管原位癌(71.2%)的差异最大。减重组的 10 年总体生存率高于对照组,分别为 93.3%和 80.6%(P<0.001)。
与未接受减重手术的相似患者相比,减重手术可降低癌症风险并提供生存优势。